These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36752579)

  • 1. Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions.
    De Falco V; Suarato G; Napolitano R; Argenziano G; Famiglietti V; Amato A; Servetto A; Bianco R; Formisano L; Terrano V; Esposito A; Giugliano MC; Ciardiello D; Ciardiello F; Napolitano S; Troiani T
    Int J Cancer; 2023 Jul; 153(1):133-140. PubMed ID: 36752579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.
    Zhong J; Sun W; Hu T; Wang C; Yan W; Luo Z; Liu X; Xu Y; Chen Y
    Cancer Med; 2023 May; 12(10):11475-11482. PubMed ID: 37016119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world outcomes of patients with resected stage III melanoma treated with adjuvant therapies.
    Dima D; Lopetegui-Lia N; Ogbue O; Osantowski B; Ullah F; Jia X; Song JM; Gastman B; Isaacs J; Kennedy LB; Funchain P
    Cancer Med; 2024 Jun; 13(12):e7257. PubMed ID: 39031560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment management for
    Haist M; Stege H; Rogall F; Tan Y; von Wasielewski I; Klespe KC; Meier F; Mohr P; Kähler KC; Weichenthal M; Hauschild A; Schadendorf D; Ugurel S; Lodde G; Zimmer L; Gutzmer R; Debus D; Schilling B; Kreuter A; Ulrich J; Meiss F; Herbst R; Forschner A; Leiter U; Pfoehler C; Kaatz M; Ziller F; Hassel JC; Tronnier M; Sachse M; Dippel E; Terheyden P; Berking C; Heppt MV; Kiecker F; Haferkamp S; Gebhardt C; Simon JC; Grabbe S; Loquai C
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
    Dummer R; Hauschild A; Santinami M; Atkinson V; Mandalà M; Kirkwood JM; Chiarion Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Gasal E; Tan M; Long GV; Schadendorf D
    N Engl J Med; 2020 Sep; 383(12):1139-1148. PubMed ID: 32877599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
    Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
    N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected
    Hauschild A; Dummer R; Schadendorf D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Haas T; Shilkrut M; Gasal E; Kefford R; Kirkwood JM; Long GV
    J Clin Oncol; 2018 Dec; 36(35):3441-3449. PubMed ID: 30343620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
    Bhave P; Pallan L; Long GV; Menzies AM; Atkinson V; Cohen JV; Sullivan RJ; Chiarion-Sileni V; Nyakas M; Kahler K; Hauschild A; Plummer R; Trojaniello C; Ascierto PA; Zimmer L; Schadendorf D; Allayous C; Lebbe C; Maurichi A; Santinami M; Roy S; Robert C; Lesimple T; Patel S; Versluis JM; Blank CU; Khattak A; Van der Westhuizen A; Carlino MS; Shackleton M; Haydon A
    Br J Cancer; 2021 Feb; 124(3):574-580. PubMed ID: 33087895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of salvage therapies after failure of adjuvant anti-PD-1 monotherapy for melanoma in the Chinese population: a multi-institutional cohort study.
    Jia DD; Xu Y; Li T; Yang JL; Chen Y; Li T
    Invest New Drugs; 2023 Jun; 41(3):431-437. PubMed ID: 37093349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.
    Li T; Jia DD; Teng LS
    Invest New Drugs; 2020 Oct; 38(5):1334-1341. PubMed ID: 32072356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.
    Schumann K; Mauch C; Klespe KC; Loquai C; Nikfarjam U; Schlaak M; Akçetin L; Kölblinger P; Hoellwerth M; Meissner M; Mengi G; Braun AD; Mengoni M; Dummer R; Mangana J; Sindrilaru MA; Radmann D; Hafner C; Freund J; Rappersberger K; Weihsengruber F; Meiss F; Reinhardt L; Meier F; Rainer B; Richtig E; Ressler JM; Höller C; Eigentler T; Amaral T; Peitsch WK; Hillen U; Harth W; Ziller F; Schatton K; Gambichler T; Susok L; Maul LV; Läubli H; Debus D; Weishaupt C; Börger S; Sievers K; Haferkamp S; Zenderowski V; Nguyen VA; Wanner M; Gutzmer R; Terheyden P; Kähler K; Emmert S; Thiem A; Sachse M; Gercken-Riedel S; Kaune KM; Thoms KM; Heinzerling L; Heppt MV; Tratzmiller S; Hoetzenecker W; Öllinger A; Steiner A; Peinhaupt T; Podda M; Schmid S; Wollina U; Biedermann T; Posch C
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):894-906. PubMed ID: 36433688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.
    Taylor AM; McKeown J; Dimitriou F; Jacques SK; Zimmer L; Allayous C; Yeoh HL; Haydon A; Ressler JM; Galea C; Woodford R; Kahler K; Hauschild A; Festino L; Hoeller C; Schwarze JK; Neyns B; Wicky A; Michielin O; Placzke J; Rutkowski P; Johnson DB; Lebbe C; Dummer R; Ascierto PA; Lo S; Long GV; Carlino MS; Menzies AM
    Eur J Cancer; 2024 Mar; 199():113561. PubMed ID: 38278009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
    Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
    Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study.
    Lodde GC; Hassel J; Wulfken LM; Meier F; Mohr P; Kähler K; Hauschild A; Schilling B; Loquai C; Berking C; Hüning S; Eckardt J; Gutzmer R; Reinhardt L; Glutsch V; Nikfarjam U; Erdmann M; Beckmann CL; Stang A; Kowall B; Galetzka W; Roesch A; Ugurel S; Zimmer L; Schadendorf D; Forschner A; Livingstone E
    Eur J Cancer; 2023 Sep; 191():112957. PubMed ID: 37487400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma.
    Holmstroem RB; Pedersen S; Jurlander R; Madsen K; Donia M; Ruhlmann CH; Schmidt H; Haslund CA; Bastholt L; Svane IM; Ellebaek E
    Eur J Cancer; 2024 May; 202():114023. PubMed ID: 38518533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
    Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
    Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which adjuvant treatment for patients with BRAF
    Funck-Brentano E; Malissen N; Roger A; Lebbé C; Deilhes F; Frénard C; Dréno B; Meyer N; Grob JJ; Tétu P; Saiag P
    Ann Dermatol Venereol; 2021 Sep; 148(3):145-155. PubMed ID: 33579557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises.
    Bhave P; Haydon A
    Australas J Dermatol; 2020 Aug; 61(3):203-209. PubMed ID: 32403192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients.
    Mojtahed SA; Boyer NR; Rao SA; Gajewski TF; Tseng J; Turaga KK
    Ann Surg Oncol; 2021 Dec; 28(13):9039-9047. PubMed ID: 34129153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.